NOTICES CONCERNING THE EUROPEAN ECONOMIC AREA

STANDING COMMITTEE OF THE EFTA STATES

Medicinal Products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2022

(2023/C 87/08)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2022, at their meeting on 28 October 2022:

Annex I List of new marketing authorisations

Annex II List of renewed marketing authorisations

Annex III List of extended marketing authorisations

Annex IV List of withdrawn marketing authorisations

Annex V List of suspended marketing authorisations

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2022:

EU-Number	Product	Country	Date of authorisation
EU/1/21/1540	Dasatinib Accord	Norway	7.4.2022
EU/1/21/1540	Dasatinib Accord	Iceland	8.4.2022
EU/1/21/1540	Dasatinib Accord	Liechtenstein	31.3.2022
EU/1/21/1541	Dasatinib Accordpharma	Norway	7.4.2022
EU/1/21/1541	Dasatinib Accordpharma	Iceland	8.4.2022
EU/1/21/1541	Dasatinib Accordpharma	Liechtenstein	31.3.2022
EU/1/21/1569	QINLOCK	Norway	11.1.2022
EU/1/21/1578	Ontilyv	Norway	25.2.2022
EU/1/21/1578	Ontilyv	Iceland	24.2.2022
EU/1/21/1578	Ontilyv	Liechtenstein	28.2.2022
EU/1/21/1579	Nexviadyme	Liechtenstein	30.6.2022
EU/1/21/1586	Voraxaze	Norway	24.1.2022
EU/1/21/1586	Voraxaze	Iceland	10.2.2022
EU/1/21/1586	Voraxaze	Liechtenstein	31.1.2022
EU/1/21/1596	Tepmetko	Norway	22.2.2022
EU/1/21/1596	Tepmetko	Iceland	22.2.2022
EU/1/21/1596	Tepmetko	Liechtenstein	28.2.2022
EU/1/21/1598	Sitagliptin SUN	Norway	3.1.2022
EU/1/21/1599	Vyepti	Norway	7.2.2022
EU/1/21/1599	Vyepti	Iceland	28.1.2022
EU/1/21/1599	Vyepti	Liechtenstein	31.1.2022
EU/1/21/1600	Tecovirimat SIGA	Norway	17.1.2022
EU/1/21/1600	Tecovirimat SIGA	Iceland	14.1.2022
EU/1/21/1600	Tecovirimat SIGA	Liechtenstein	31.1.2022
EU/1/21/1602	Uplizna	Norway	16.5.2022
EU/1/21/1602	Uplizna	Iceland	13.5.2022
EU/1/21/1602	Uplizna	Liechtenstein	30.4.2022
EU/1/21/1603	Lumykras	Norway	11.1.2022
EU/1/21/1603	Lumykras	Iceland	25.1.2022
EU/1/21/1603	Lumykras	Liechtenstein	31.1.2022
EU/1/21/1604	Riltrava Aerosphere	Norway	11.1.2022
EU/1/21/1604	Riltrava Aerosphere	Iceland	19.1.2022
EU/1/21/1604	Riltrava Aerosphere	Liechtenstein	31.1.2022

EU-Number	Product	Country	Date of authorisation
EU/1/21/1605	Tavneos	Norway	19.1.2022
EU/1/21/1605	Tavneos	Iceland	14.2.2022
EU/1/21/1605	Tavneos	Liechtenstein	31.1.2022
EU/1/21/1606	Yselty	Norway	22.6.2022
EU/1/21/1606	Yselty	Iceland	21.6.2022
EU/1/21/1606	Yselty	Liechtenstein	30.6.2022
EU/1/21/1607	Lonapegsomatropin Ascendis Pharma	Norway	21.1.2022
EU/1/21/1607	Lonapegsomatropin Ascendis Pharma	Iceland	1.2.2022
EU/1/21/1607	Lonapegsomatropin Ascendis Pharma	Liechtenstein	31.1.2022
EU/1/21/1608	Wegovy	Norway	12.1.2022
EU/1/21/1608	Wegovy	Iceland	19.1.2022
EU/1/21/1608	Wegovy	Liechtenstein	31.1.2022
EU/1/21/1611	Vildagliptin/Metformin hydrochloride Accord	Norway	06.4.2022
EU/1/21/1611	Vildagliptin/Metformin hydrochloride Accord	Iceland	19.4.2022
EU/1/21/1611	Vildagliptin/Metformin hydrochloride Accord	Liechtenstein	31.3.2022
EU/1/21/1612	Apexxnar	Norway	22.2.2022
EU/1/21/1612	Apexxnar	Iceland	22.2.2022
EU/1/21/1612	Apexxnar	Liechtenstein	28.2.2022
EU/1/21/1615	Padcev	Norway	21.4.2022
EU/1/21/1615	Padcev	Iceland	4.5.2022
EU/1/21/1615	Padcev	Liechtenstein	30.4.2022
EU/1/21/1616	Kerendia	Norway	22.2.2022
EU/1/21/1616	Kerendia	Iceland	24.2.2022
EU/1/21/1616	Kerendia	Liechtenstein	28.2.2022
EU/1/21/1617	Ngenla	Norway	22.2.2022
EU/1/21/1617	Ngenla	Iceland	22.2.2022
EU/1/21/1617	Ngenla	Liechtenstein	28.2.2022
EU/1/21/1619	Sitagliptin/Metformin hydrochloride Mylan	Norway	24.3.2022
EU/1/21/1619	Sitagliptin/Metformin hydrochloride Mylan	Iceland	15.3.2022
EU/1/21/1619	Sitagliptin/Metformin hydrochloride Mylan	Liechtenstein	28.2.2022
EU/1/21/1620	Sapropterin Dipharma	Norway	22.2.2022
EU/1/21/1620	Sapropterin Dipharma	Iceland	22.2.2022

EU-Number	Product	Country	Date of authorisation
EU/1/21/1620	Sapropterin Dipharma	Liechtenstein	28.2.2022
EU/1/21/1621	OKEDI	Norway	21.2.2022
EU/1/21/1621	OKEDI	Iceland	16.2.2022
EU/1/21/1621	OKEDI	Liechtenstein	28.2.2022
EU/1/21/1622	Oxbryta	Norway	21.2.2022
EU/1/21/1622	Oxbryta	Iceland	22.2.2022
EU/1/21/1622	Oxbryta	Liechtenstein	28.2.2022
EU/1/21/1623	Saphnelo	Norway	21.2.2022
EU/1/21/1623	Saphnelo	Iceland	21.2.2022
EU/1/21/1623	Saphnelo	Liechtenstein	28.2.2022
EU/1/21/1624	Covid-19 Vaccine (inactivated, adjuvanted) Valneva	Norway	27.6.2022
EU/1/21/1624	COVID-19 Vaccine (inactivated, adjuvanted) Valneva	Iceland	28.6.2022
EU/1/21/1624	COVID-19 Vaccine (inactivated, adjuvanted) Valneva	Liechtenstein	30.6.2022
EU/1/22/1625	Paxlovid	Norway	28.1.2022
EU/1/22/1625	Paxlovid	Iceland	1.2.2022
EU/1/22/1625	Paxlovid	Liechtenstein	31.1.2022
EU/1/22/1628	Sondelbay	Norway	7.4.2022
EU/1/22/1628	Sondelbay	Iceland	20.4.2022
EU/1/22/1628	Sondelbay	Liechtenstein	31.3.2022
EU/1/22/1629	Zolsketil pegylated liposomal	Iceland	10.6.2022
EU/1/22/1629	Zolsketil pegylated liposomal	Liechtenstein	31.5.2022
EU/1/22/1630	Kimmtrak	Norway	12.4.2022
EU/1/22/1630	Kimmtrak	Iceland	27.4.2022
EU/1/22/1630	Kimmtrak	Liechtenstein	30.4.2022
EU/1/22/1631	Breyanzi	Norway	20.4.2022
EU/1/22/1631	Breyanzi	Iceland	4.5.2022
EU/1/22/1631	Breyanzi	Liechtenstein	30.4.2022
EU/1/22/1632	Stimufend	Norway	7.4.2022
EU/1/22/1632	Stimufend	Iceland	20.4.2022
EU/1/22/1632	Stimufend	Liechtenstein	31.3.2022
EU/1/22/1633	Sitagliptin Accord	Norway	16.5.2022
EU/1/22/1633	Sitagliptin Accord	Iceland	17.5.2022
EU/1/22/1633	Sitagliptin Accord	Liechtenstein	30.4.2022
EU/1/22/1634	Dimethyl Fumarate Mylan	Norway	23.5.2022

EU-Number	Product	Country	Date of authorisation
EU/1/22/1634	Dimethyl Fumarate Mylan	Iceland	18.5.2022
EU/1/22/1634	Dimethyl fumarate Mylan	Liechtenstein	31.5.2022
EU/1/22/1635	Dimethyl fumarate Polpharma	Norway	20.5.2022
EU/1/22/1635	Dimethyl fumarate Polpharma	Iceland	19.5.2022
EU/1/22/1635	Dimethyl fumarate Polpharma	Liechtenstein	31.5.2022
EU/1/22/1637	Dimethyl fumarate Neuraxpharm	Norway	20.5.2022
EU/1/22/1637	Dimethyl fumarate Neuraxpharm	Iceland	19.5.2022
EU/1/22/1637	Dimethyl fumarate Neuraxpharm	Liechtenstein	31.5.2022
EU/1/22/1638	Quviviq	Norway	20.5.2022
EU/1/22/1638	Quviviq	Iceland	28.6.2022
EU/1/22/1638	Quviviq	Liechtenstein	30.4.2022
EU/1/22/1639	Truvelog Mix 30	Norway	29.4.2022
EU/1/22/1639	Truvelog Mix 30	Iceland	12.5.2022
EU/1/22/1639	Truvelog Mix 30	Liechtenstein	30.4.2022
EU/1/22/1640	Amversio	Norway	20.5.2022
EU/1/22/1640	Amversio	Iceland	19.5.2022
EU/1/22/1640	Amversio	Liechtenstein	31.5.2022
EU/1/22/1641	PreHevbri	Norway	16.5.2022
EU/1/22/1641	PreHevbri	Iceland	18.5.2022
EU/1/22/1641	PreHevbri	Liechtenstein	30.4.2022
EU/1/22/1642	Orgovyx	Norway	16.5.2022
EU/1/22/1642	Orgovyx	Iceland	12.5.2022
EU/1/22/1642	Orgovyx	Liechtenstein	30.4.2022
EU/1/22/1643	Kapruvia	Norway	25.4.2022
EU/1/22/1643	Kapruvia	Iceland	11.5.2022
EU/1/22/1643	Kapruvia	Liechtenstein	30.4.2022
EU/1/22/1644	Inpremzia	Norway	20.5.2022
EU/1/22/1644	Inpremzia	Iceland	18.5.2022
EU/1/22/1644	Inpremzia	Liechtenstein	30.4.2022
EU/1/22/1645	Vydura	Norway	29.4.2022
EU/1/22/1645	Vydura	Iceland	11.5.2022
EU/1/22/1645	Vydura	Liechtenstein	30.4.2022
EU/1/22/1646	Amifampridine SERB	Norway	31.5.2022

EU-Number	Product	Country	Date of authorisation
EU/1/22/1646	Amifampridine SERB	Liechtenstein	31.5.2022
EU/1/22/1647	Camcevi	Norway	31.5.2022
EU/1/22/1647	Camcevi	Iceland	9.6.2022
EU/1/22/1647	Camcevi	Liechtenstein	31.5.2022
EU/1/22/1648	Carvykti	Norway	31.5.2022
EU/1/22/1648	Carvykti	Iceland	9.6.2022
EU/1/22/1648	Carvykti	Liechtenstein	31.5.2022
EU/1/22/1649	Lunsumio	Norway	16.6.2022
EU/1/22/1649	Lunsumio	Iceland	15.6.2022
EU/1/22/1649	Lunsumio	Liechtenstein	30.6.2022
EU/1/22/1650	Tabrecta	Liechtenstein	30.6.2022
EU/1/22/1651	Evusheld	Norway	28.3.2022
EU/1/22/1651	Evusheld	Iceland	30.3.2022
EU/1/22/1651	Evusheld	Liechtenstein	31.3.2022
EU/1/22/1652	Filsuvez	Liechtenstein	30.6.2022
EU/1/22/1655	Pirfenidone AET	Liechtenstein	30.6.2022
EU/1/22/1659	Xenpozyme	Liechtenstein	30.6.2022
EU/2/21/279	Zenalpha	Norway	7.1.2022
EU/2/21/280	Imoxat	Norway	7.1.2022
EU/2/21/281	CircoMax	Norway	17.1.2022
EU/2/21/281	CircoMax	Liechtenstein	31.1.2022
EU/2/22/282	RenuTend	Norway	29.4.2022
EU/2/22/282	RenuTend	Iceland	24.5.2022
EU/2/22/282	RenuTend	Liechtenstein	30.4.2022
EU/2/22/283	Chanaxin	Norway	9.6.2022
EU/2/22/283	Chanaxin	Iceland	14.6.2022
EU/2/22/283	Chanaxin	Liechtenstein	30.4.2022

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2022:

EU-Number	Product	Country	Date of authorisation
EU/1/11/699	Fampyra	Norway	9.5.2022
EU/1/11/699	Fampyra	Liechtenstein	30.4.2022
EU/1/11/749	Caprelsa	Norway	24.1.2022
EU/1/11/749	Caprelsa	Iceland	20.1.2022
EU/1/11/749	Caprelsa	Liechtenstein	31.1.2022
EU/1/12/782	Kalydeco	Norway	20.5.2022
EU/1/12/782	Kalydeco	Liechtenstein	30.4.2022
EU/1/12/784	Cuprymina	Iceland	28.6.2022
EU/1/12/784	Cuprymina	Liechtenstein	30.6.2022
EU/1/13/818	Bosulif	Norway	16.5.2022
EU/1/13/818	Bosulif	Iceland	20.4.2022
EU/1/13/818	Bosulif	Liechtenstein	31.3.2022
EU/1/13/875	Deltyba	Norway	30.3.2022
EU/1/13/875	Deltyba	Iceland	6.4.2022
EU/1/13/875	Deltyba	Liechtenstein	31.3.2022
EU/1/13/901	Sirturo	Norway	26.1.2022
EU/1/13/901	Sirturo	Iceland	14.1.2022
EU/1/13/901	Sirturo	Liechtenstein	31.1.2022
EU/1/13/902	Translarna	Iceland	28.6.2022
EU/1/13/902	Translarna	Liechtenstein	30.6.2022
EU/1/14/987	Holoclar	Norway	8.4.2022
EU/1/14/987	Holoclar	Iceland	11.1.2022
EU/1/14/987	Holoclar	Liechtenstein	31.1.2022
EU/1/15/1078	Natpar	Norway	19.4.2022
EU/1/15/1078	Natpar	Iceland	6.4.2022
EU/1/15/1078	Natpar	Liechtenstein	31.3.2022
EU/1/15/999	Zykadia	Norway	22.2.2022
EU/1/15/999	Zykadia	Iceland	22.2.2022
EU/1/15/999	Zykadia	Liechtenstein	28.2.2022
EU/1/16/1086	Tagrisso	Norway	6.4.2022
EU/1/16/1086	Tagrisso	Iceland	20.4.2022
EU/1/16/1086	Tagrisso	Liechtenstein	31.3.2022

EU-Number	Product	Country	Date of authorisation
EU/1/16/1089	Pandemic influenza vaccine H5N1 AstraZeneca	Norway	8.4.2022
EU/1/16/1089	Pandemic influenza vaccine H5N1 AstraZeneca	Iceland	16.3.2022
EU/1/16/1089	Pandemic influenza vaccine H5N1 AstraZeneca	Liechtenstein	31.3.2022
EU/1/16/1101	Darzalex	Norway	21.1.2022
EU/1/16/1101	Darzalex	Iceland	14.1.2022
EU/1/16/1101	Darzalex	Liechtenstein	31.1.2022
EU/1/16/1139	Ocaliva	Norway	24.1.2022
EU/1/16/1139	Ocaliva	Iceland	21.1.2022
EU/1/16/1139	Ocaliva	Liechtenstein	31.1.2022
EU/1/16/1152	Roteas	Norway	13.1.2022
EU/1/16/1152	Roteas	Iceland	11.1.2022
EU/1/16/1152	Roteas	Liechtenstein	31.1.2022
EU/1/16/1154	Vemlidy	Norway	4.1.2022
EU/1/16/1154	Vemlidy	Iceland	5.1.2022
EU/1/16/1154	Vemlidy	Liechtenstein	31.1.2022
EU/1/16/1155	Kyntheum	Norway	29.4.2022
EU/1/16/1155	Kyntheum	Iceland	11.5.2022
EU/1/16/1155	Kyntheum	Liechtenstein	30.4.2022
EU/1/16/1171	Ledaga	Norway	17.1.2022
EU/1/16/1171	Ledaga	Iceland	14.1.2022
EU/1/16/1171	Ledaga	Liechtenstein	31.1.2022
EU/1/17/1172	Jylamvo	Norway	24.1.2022
EU/1/17/1172	Jylamvo	Iceland	5.1.2022
EU/1/17/1172	Jylamvo	Liechtenstein	31.1.2022
EU/1/17/1174	Rolufta Ellipta	Norway	14.1.2022
EU/1/17/1174	Rolufta Ellipta	Iceland	14.1.2022
EU/1/17/1174	Rolufta Ellipta	Liechtenstein	31.1.2022
EU/1/17/1175	Daptomycin Hospira	Norway	13.1.2022
EU/1/17/1175	Daptomycin Hospira	Iceland	25.1.2022
EU/1/17/1176	Yargesa	Norway	24.1.2022
EU/1/17/1176	Yargesa	Iceland	20.1.2022
EU/1/17/1176	Yargesa	Liechtenstein	31.1.2022
EU/1/17/1178	Xeljanz	Norway	14.3.2022
EU/1/17/1178	Xeljanz	Iceland	15.3.2022
EU/1/17/1178	Xeljanz	Liechtenstein	31.3.2022

EU-Number	Product	Country	Date of authorisation
EU/1/17/1179	Veltassa	Norway	6.4.2022
EU/1/17/1179	Veltassa	Iceland	19.4.2022
EU/1/17/1179	Veltassa	Liechtenstein	31.3.2022
EU/1/17/1181	Spherox	Norway	8.6.2022
EU/1/17/1181	Spherox	Iceland	19.5.2022
EU/1/17/1181	Spherox	Liechtenstein	30.4.2022
EU/1/17/1182	Emtricitabine/Tenofovir disoproxil Krka d.d	Norway	24.1.2022
EU/1/17/1182	Emtricitabine/Tenofovir disoproxil Krka d.d.	Iceland	21.1.2022
EU/1/17/1182	Emtricitabine /Tenofovir disoproxil Krka d.d.	Liechtenstein	31.1.2022
EU/1/17/1184	Riximyo	Norway	22.2.2022
EU/1/17/1184	Riximyo	Iceland	23.2.2022
EU/1/17/1184	Riximyo	Liechtenstein	28.2.2022
EU/1/17/1185	Rixathon	Norway	14.3.2022
EU/1/17/1185	Rixathon	Iceland	15.3.2022
EU/1/17/1185	Rixathon	Liechtenstein	28.2.2022
EU/1/17/1186	Axumin	Norway	16.2.2022
EU/1/17/1186	Axumin	Iceland	16.2.2022
EU/1/17/1186	Axumin	Liechtenstein	28.2.2022
EU/1/17/1187	Trumenba	Norway	9.5.2022
EU/1/17/1187	Trumenba	Iceland	11.5.2022
EU/1/17/1187	Trumenba	Liechtenstein	30.4.2022
EU/1/17/1188	Spinraza	Norway	7.2.2022
EU/1/17/1188	Spinraza	Iceland	11.2.2022
EU/1/17/1188	Spinraza	Liechtenstein	31.1.2022
EU/1/17/1189	Elmiron	Norway	26.1.2022
EU/1/17/1189	Elmiron	Iceland	21.1.2022
EU/1/17/1189	Elmiron	Liechtenstein	31.1.2022
EU/1/17/1190	Ivabradine Accord	Norway	18.2.2022
EU/1/17/1190	Ivabradine Accord	Iceland	22.2.2022
EU/1/17/1190	Ivabradine Accord	Liechtenstein	28.2.2022
EU/1/17/1191	Qarziba	Norway	27.1.2022
EU/1/17/1191	Qarziba	Iceland	19.1.2022
EU/1/17/1191	Qarziba	Liechtenstein	31.1.2022
EU/1/17/1192	Brineura	Liechtenstein	31.3.2022
EU/1/17/1192	Brineura	Norway	15.5.2022

EU-Number	Product	Country	Date of authorisation
EU/1/17/1193	Refixia	Norway	5.4.2022
EU/1/17/1193	Refixia	Iceland	15.3.2022
EU/1/17/1193	Refixia	Liechtenstein	28.2.2022
EU/1/17/1194	Febuxostat Mylan	Norway	21.2.2022
EU/1/17/1194	Febuxostat Mylan	Iceland	23.2.2022
EU/1/17/1194	Febuxostat Mylan	Liechtenstein	28.2.2022
EU/1/17/1195	Erelzi	Iceland	27.4.2022
EU/1/17/1195	Erelzi	Liechtenstein	30.4.2022
EU/1/17/1196	Kevzara	Norway	9.5.2022
EU/1/17/1196	Kevzara	Iceland	11.5.2022
EU/1/17/1196	Kevzara	Liechtenstein	30.4.2022
EU/1/17/1197	Oxervate	Norway	12.4.2022
EU/1/17/1197	Oxervate	Iceland	20.4.2022
EU/1/17/1197	Oxervate	Liechtenstein	31.3.2022
EU/1/17/1200	Besponsa	Norway	22.2.2022
EU/1/17/1200	Besponsa	Iceland	21.2.2022
EU/1/17/1200	Besponsa	Liechtenstein	28.2.2022
EU/1/17/1201	Skilarence	Norway	24.2.2022
EU/1/17/1201	Skilarence	Iceland	24.2.2022
EU/1/17/1201	Skilarence	Liechtenstein	28.2.2022
EU/1/17/1202	Ucedane	Norway	29.4.2022
EU/1/17/1202	Ucedane	Iceland	25.4.2022
EU/1/17/1202	Ucedane	Liechtenstein	31.3.2022
EU/1/17/1203	Insulin lispro Sanofi	Norway	29.4.2022
EU/1/17/1203	Insulin lispro Sanofi	Iceland	3.5.2022
EU/1/17/1203	Insulin lispro Sanofi	Liechtenstein	31.3.2022
EU/1/17/1205	Blitzima	Norway	29.4.2022
EU/1/17/1205	Blitzima	Iceland	6.5.2022
EU/1/17/1205	Blitzima	Liechtenstein	30.4.2022
EU/1/17/1208	Trimbow	Norway	31.3.2022
EU/1/17/1208	Trimbow	Iceland	19.4.2022
EU/1/17/1208	Trimbow	Liechtenstein	31.3.2022
EU/1/17/1209	Reagila	Norway	20.4.2022
EU/1/17/1209	Reagila	Iceland	20.4.2022
EU/1/17/1209	Reagila	Liechtenstein	30.4.2022
EU/1/17/1210	Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva	Norway	31.5.2022

EU-Number	Product	Country	Date of authorisation
EU/1/7/1210	Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva	Iceland	9.6.2022
EU/1/17/1210	Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva	Liechtenstein	31.5.2022
EU/1/17/1212	Mavenclad	Norway	29.4.2022
EU/1/17/1212	Mavenclad	Iceland	11.5.2022
EU/1/17/1212	Mavenclad	Liechtenstein	30.4.2022
EU/1/17/1213	Maviret	Iceland	20.4.2022
EU/1/17/1213	Maviret	Liechtenstein	31.3.2022
EU/1/17/1216	Imraldi	Norway	9.5.2022
EU/1/17/1216	Imraldi	Iceland	17.5.2022
EU/1/17/1216	Imraldi	Liechtenstein	30.4.2022
EU/1/17/1218	Rydapt	Iceland	10.6.2022
EU/1/17/1218	Rydapt	Liechtenstein	31.5.2022
EU/1/17/1220	Tecentriq	Norway	29.4.2022
EU/1/17/1220	Tecentriq	Iceland	6.5.2022
EU/1/17/1220	Tecentriq	Liechtenstein	30.4.2022
EU/1/17/1221	Kisqali	Norway	20.4.2022
EU/1/17/1221	Kisqali	Iceland	27.4.2022
EU/1/17/1221	Kisqali	Liechtenstein	30.4.2022
EU/1/17/1222	Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	Iceland	9.6.2022
EU/1/17/1222	Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	Liechtenstein	31.5.2022
EU/1/17/1223	Vosevi	Norway	20.5.2022
EU/1/17/1223	Vosevi	Liechtenstein	31.5.2022
EU/1/17/1224	Xermelo	Liechtenstein	30.6.2022
EU/1/17/1225	Symtuza	Norway	31.5.2022
EU/1/17/1225	Symtuza	Iceland	9.6.2022
EU/1/17/1225	Symtuza	Liechtenstein	31.5.2022
EU/1/17/1227	Entecavir Mylan	Liechtenstein	30.6.2022
EU/1/17/1250	Rubraca	Norway	24.3.2022
EU/1/17/1250	Rubraca	Iceland	16.3.2022
EU/1/17/1250	Rubraca	Liechtenstein	31.3.2022
EU/1/17/1262	Crysvita	Norway	11.2.2022
EU/1/17/1262	Crysvita	Iceland	25.1.2022
EU/1/17/1262	Crysvita	Liechtenstein	31.1.2022
EU/1/18/1345	Ondexxya	Norway	30.6.2022
EU/1/18/1345	Ondexxya	Iceland	17.5.2022

EU-Number	Product	Country	Date of authorisation
EU/1/18/1345	Ondexxya	Liechtenstein	30.4.2022
EU/1/19/1355	Lorviqua	Iceland	25.4.2022
EU/1/19/1355	Lorviqua	Liechtenstein	30.4.2022
EU/1/19/1360	Waylivra	Norway	24.2.2022
EU/1/19/1360	Waylivra	Iceland	21.2.2022
EU/1/19/1360	Waylivra	Liechtenstein	28.2.2022
EU/1/20/1437	Dovprela	Liechtenstein	30.6.2022
EU/1/20/1443	Zolgensma	Norway	31.5.2022
EU/1/20/1443	Zolgensma	Iceland	9.6.2022
EU/1/20/1443	Zolgensma	Liechtenstein	31.5.2022
EU/1/20/1446	Hepcludex	Liechtenstein	30.6.2022
EU/1/20/1459	Veklury	Norway	29.4.2022
EU/1/20/1459	Veklury	Iceland	4.5.2022
EU/1/20/1459	Veklury	Liechtenstein	30.4.2022
EU/1/20/1460	Rozlytrek	Liechtenstein	31.5.2022
EU/1/20/1474	BLENREP	Liechtenstein	30.6.2022
EU/1/20/1525	COVID- 19 Vaccine Janssen (JCOVDEN)	Norway	24.1.2022
EU/1/20/1525	COVID-19 Vaccine Janssen (JCOVDEN)	Iceland	14.2.2022
EU/1/20/1525	COVID-19 Vaccine Janssen (JCOVDEN)	Liechtenstein	31.1.2022
EU/1/20/1527	Retsevmo	Norway	26.1.2022
EU/1/20/1527	Retsevmo	Iceland	4.1.2022
EU/1/21/1535	Pemazyre	Norway	22.2.2022
EU/1/21/1535	Pemazyre	Iceland	23.2.2022
EU/1/21/1535	Pemazyre	Liechtenstein	28.2.2022
EU/1/21/1537	NEXPOVIO	Norway	2.6.2022
EU/1/21/1537	NEXPOVIO	Iceland	19.5.2022
EU/1/21/1537	NEXPOVIO	Liechtenstein	31.5.2022
EU/1/21/1538	Jemperli	Norway	22.2.2022
EU/1/21/1538	Jemperli	Iceland	22.2.2022
EU/1/21/1538	Jemperli	Liechtenstein	28.2.2022
EU/1/21/1539	Abecma	Liechtenstein	30.6.2022
EU/1/21/1552	Koselugo	Norway	12.5.2022
EU/1/21/1552	Koselugo	Liechtenstein	30.4.2022
EU/2/16/203	VarroMed	Norway	24.1.2022
EU/2/16/203	VarroMed	Iceland	21.1.2022

EU-Number	Product	Country	Date of authorisation
EU/2/16/203	VarroMed	Liechtenstein	31.1.2022
EU/2/17/205	Cytopoint	Norway	29.6.2022
EU/2/17/205	Cytopoint	Liechtenstein	30.4.2022
EU/2/17/206	Credelio	Norway	29.6.2022
EU/2/17/206	Credelio	Liechtenstein	30.4.2022
EU/2/17/207	Zulvac BTV	Norway	29.6.2022
EU/2/17/207	Zulvac BTV	Liechtenstein	30.4.2022
EU/2/17/209	RESPIPORC FLUpan H1N1	Norway	29.6.2022
EU/2/17/209	RESPIPORC FLUpan H1N1	Liechtenstein	30.4.2022
EU/2/17/210	Zeleris	Norway	30.6.2022
EU/2/17/210	Zeleris	Iceland	18.5.2022
EU/2/17/210	Zeleris	Liechtenstein	31.5.2022

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2022:

EU-Number	Product	Country	Date of authorisation
EU/1/05/320/005	Noxafil	Liechtenstein	31.1.2022
EU/1/05/320/005	Noxafil	Norway	24.1.2022
EU/1/05/320/005	Noxafil	Iceland	20.1.2022
EU/1/05/324	Naglazyme	Liechtenstein	30.4.2022
EU/1/13/837	Tecfidera	Liechtenstein	31.5.2022
EU/1/14/930	Jardiance	Liechtenstein	31.3.2022
EU/1/14/936/008	Nuwiq	Liechtenstein	31.1.2022
EU/1/14/936/008	Nuwiq	Norway	24.1.2022
EU/1/14/936/008	Nuwiq	Iceland	20.1.2022
EU/1/15/1043/009-010	Nucala	Liechtenstein	30.4.2022
EU/1/15/1043/009-010	Nucala	Norway	24.5.2022
EU/1/15/1043/009-010	Nucala	Iceland	23.6.2022
EU/1/16/1116/003-004	Epclusa	Liechtenstein	31.1.2022
EU/1/16/1116/003-004	Epclusa	Norway	7.1.2022
EU/1/16/1116/003-004	Epclusa	Iceland	18.1.2022
EU/1/17/1217/004	Nitisinone MDK	Iceland	5.1.2022
EU/1/17/1229/021-022	Dupixent	Liechtenstein	30.4.2022
EU/1/17/1229/021 -022	Dupixent	Iceland	27.4.2022
EU/1/17/1235/004-005	Zejula	Liechtenstein	31.5.2022
EU/1/17/1235/004-005	Zejula	Norway	30.5.2022
EU/1/17/1235/004-005	Zejula	Iceland	10.6.2022
EU/1/17/1247/015-016	Adynovi	Liechtenstein	31.1.2022
EU/1/17/1247/015-016	Adynovi	Norway	14.1.2022
EU/1/17/1247/015-016	Adynovi	Iceland	20.1.2022
EU/1/17/1251/010-011	Ozempic	Liechtenstein	31.1.2022
EU/1/17/1251/010-011	Ozempic	Norway	11.1.2022
EU/1/17/1251/010-011	Ozempic	Iceland	20.1.2022
EU/1/18/1274/006-008	Trydonis	Liechtenstein	31.1.2022
EU/1/18/1274/006-008	Trydonis	Norway	24.1.2022
EU/1/18/1274/006-008	Trydonis	Iceland	21.1.2022
EU/1/18/1323/003	Ilumetri	Liechtenstein	30.4.2022
EU/1/18/1323/003	Ilumetri	Norway	20.5.2022
EU/1/18/1323/003	Ilumetri	Iceland	28.6.2022

EU-Number	Product	Country	Date of authorisation
EU/1/19/1414/007-008	Mayzent	Liechtenstein	28.2.2022
EU/1/19/1414/007-008	Mayzent	Norway	16.2.2022
EU/1/19/1414/007-008	Mayzent	Iceland	24.2.2022
EU/1/20/1422/016-017	Lyumjev	Liechtenstein	30.4.2022
EU/1/20/1422/016-017	Lyumjev	Norway	18.5.2022
EU/1/20/1422/016-017	Lyumjev	Iceland	17.5.2022
EU/1/20/1468/002	Kaftrio	Liechtenstein	31.1.2022
EU/1/20/1468/002	Kaftrio	Norway	7.1.2022
EU/1/20/1468/002	Kaftrio	Iceland	19.1.2022
EU/1/20/1473/004-005	AYVAKYT	Liechtenstein	31.3.2022
EU/1/20/1473/004-005	AYVAKYT	Norway	31.3.2022
EU/1/20/1473/004-005	AYVAKYT	Iceland	19.4.2022
EU/1/20/1500/003-004	Xofluza	Liechtenstein	30.4.2022
EU/1/20/1500/003-004	Xofluza	Norway	29.4.2022
EU/1/20/1501/003-004	Sogroya	Liechtenstein	30.4.2022
EU/1/20/1501/003-004	Sogroya	Norway	29.4.2022
EU/1/20/1501/003-004	Sogroya	Iceland	12.5.2022
EU/1/20/1513/013-016	Yuflyma	Liechtenstein	28.2.2022
EU/1/20/1513/013-016	Yuflyma	Norway	16.2.2022
EU/1/20/1513/013-016	Yuflyma	Iceland	15.3.2022
EU/2/13/154/028-033	Apoquel	Norway	5.1.2022

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2022:

EU-Number	Product	Country	Date of withdrawal
EU/1/01/174	Starlix	Norway	16.6.2022
EU/1/01/174	Starlix	Liechtenstein	30.4.2022
EU/1/03/249	Vivanza	Norway	1.3.2022
EU/1/03/249	Vivanza	Iceland	10.2.2022
EU/1/03/249	Vivanza	Liechtenstein	28.2.2022
EU/1/03/250	Ytracis	Norway	22.2.2022
EU/1/03/250	Ytracis	Iceland	5.1.2022
EU/1/07/384	Docetaxel Zentiva	Liechtenstein	31.5.2022
EU/1/07/384	Docetaxel Zentiva	Iceland	10.6.2022
EU/1/07/421	Glubrava	Norway	8.6.2022
EU/1/07/421	Glubrava	Liechtenstein	31.5.2022
EU/1/08/491	Rasilez HCT	Norway	22.2.2022
EU/1/08/491	Rasilez HCT	Iceland	11.1.2022
EU/1/09/519	PANTOLOC Control	Norway	10.1.2022
EU/1/09/519	PANTOLOC Control	Iceland	5.1.2022
EU/1/11/695	Leganto	Norway	18.1.2022
EU/1/11/695	Leganto	Iceland	5.1.2022
EU/1/11/695	Leganto	Liechtenstein	31.1.2022
EU/1/11/728	Pramipexole Accord	Norway	22.4.2022
EU/1/11/728	Pramipexole Accord	Iceland	4.5.2022
EU/1/11/728	Pramipexole Accord	Liechtenstein	30.4.2022
EU/1/13/825	Imatinib Actavis	Liechtenstein	31.5.2022
EU/1/15/1034	Pemetrexed Lilly	Norway	23.3.2022
EU/1/15/1034	Pemetrexed Lilly	Iceland	21.1.2022
EU/1/15/1034	Pemetrexed Lilly	Liechtenstein	31.3.2022
EU/1/15/1069	Episalvan	Iceland	16.6.2022
EU/1/15/1069	Episalvan	Liechtenstein	30.6.2022
EU/1/16/1131	Thorinane	Norway	4.3.2022
EU/1/16/1131	Thorinane	Liechtenstein	31.3.2022
EU/1/17/1183	Pemetrexed Pfizer	Norway	23.3.2022
EU/1/17/1183	Pemetrexed Pfizer	Iceland	27.1.2022
EU/1/17/1183	Pemetrexed Pfizer	Liechtenstein	31.1.2022
EU/1/19/1363	Zynquista	Norway	21.4.2022

EU-Number	Product	Country	Date of withdrawal
EU/1/19/1363	Zynquista	Iceland	6.4.2022
EU/1/19/1363	Zynquista	Liechtenstein	31.3.2022
EU/1/19/1367	Zynteglo	Norway	21.4.2022
EU/1/19/1367	Zynteglo	Iceland	20.4.2022
EU/1/19/1367	Zynteglo	Liechtenstein	31.3.2022
EU/1/19/1387	Senstend	Liechtenstein	30.6.2022
EU/1/19/1421	Staquis	Norway	9.2.2022
EU/1/19/1421	Staquis	Iceland	10.2.2022
EU/1/19/1421	Staquis	Liechtenstein	31.1.2022
EU/2/14/180	Coliprotec F4	Norway	22.2.2022

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2022:

EU-Number	Product	Country	Date of suspension